Vertex Collaborates with Molecular Templates to Discover and Develop Conditioning Regimens Enhancing Hematopoietic Stem Cell Transplants

 Vertex Collaborates with Molecular Templates to Discover and Develop Conditioning Regimens Enhancing Hematopoietic Stem Cell Transplants

Vertex Collaborate with Molecular Templates to Discover & Develop Conditioning Regimens Enhancing Hematopoietic Stem Cell Transplants

Shots:

  • Molecular Templates (MTEM) to receive $38M up front including an equity investment, up to $522M as development, regulatory, commercial milestones, option payment for two targets and royalties on sales of products
  • MTEM will conduct research activities to discover a new conditioning regimen utilizing its engineered toxin body (ETB) platform for up to two targets selected by Vertex including CTX001. Additionally, Vertex will get an option to select a second target and to license selected molecules with an exclusive right to develop selected molecules for any indication
  • CTX001 is an ex vivo CRISPR/Cas9 gene editing therapy, currently being evaluated in two ongoing P-I/II studies in patients with transfusion-dependent beta thalassemia and severe sickle cell disease, where a hematopoietic stem cell transplant is required as part of treatment with CTX001

Click here to­ read full press release/ article | Ref: Vertex | Image: Pharma Advancement

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post